MedPath

Growth and Tolerance of Infants Fed Milk-Based Infant Formula

Not Applicable
Completed
Conditions
Gastro-Intestinal Tolerance
Registration Number
NCT03967132
Lead Sponsor
Abbott Nutrition
Brief Summary

The purpose of this study is to evaluate growth and tolerance of healthy term infants fed an experimental milk-based infant formula with oligosaccharides compared to a control milk-based infant formula.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
189
Inclusion Criteria
  • Good health as determined from participant's medical history
  • Singleton from a full-term birth with a gestational age of 37-42 weeks
  • Birth weight was > 2490 g (~5 lbs. 8 oz.)
  • If parent(s) of the participant elect to formula-feed the participant, parent(s) confirm the participant has not been given human milk since being discharged from the hospital following birth, and confirm their intention to feed their infant the study product as the sole source of feeding from Study Visit 1-Visit 7, unless instructed otherwise by their healthcare professional.
  • If parent(s) of the participant elect to feed the infant human milk, they confirm the infant has not received any formula prior to enrollment, and confirm their intention to exclusively feed human milk from birth, and as the sole source of feeding from Study Visit 1-Visit 7.
  • Parent(s) confirm their intention not to administer vitamin or mineral supplements (with the exception of Vitamin D supplements), solid foods or juices to their infant from enrollment through the duration of the study, unless instructed otherwise by their healthcare professional.
  • Participant's parent(s) has voluntarily signed and dated an ICF, approved by an IRB/IEC and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study.
Exclusion Criteria
  • An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development.
  • Participant is taking and plans to continue taking medications (including over the counter (OTC), such as Mylicon® for gas), prebiotics, probiotics, home remedies (such as juice for constipation), herbal preparations or rehydration fluids that might affect GI tolerance.
  • Participant participates in another study that has not been approved as a concomitant study by AN.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
WeightDay of life 14 - 119

Weight gain per day

Secondary Outcome Measures
NameTimeMethod
LengthStudy Day 1 to Day of life 119

Length gain per day

Head Circumference (HC)Study Day 1 to Day of life 119

HC gain per day

Stool CharacteristicsStudy Day 1 to Day of life 119

Parent completed diary

Illness IncidenceStudy Day 1 to Day of life 119

Parent reported incidence of illness

Formula ToleranceStudy Day 1 to Day of life 119

Parent completed diary

Trial Locations

Locations (19)

Watching Over Mothers & Babies

🇺🇸

Tucson, Arizona, United States

Pediatric Medical Associates

🇺🇸

Sacramento, California, United States

Norwich Pediatric Group, P.C.

🇺🇸

Norwich, Connecticut, United States

Phoenix Medical Research LLC

🇺🇸

Miami, Florida, United States

University Clinical Research-Deland, LLC a/b/a Accel Clinical Research

🇺🇸

Orlando, Florida, United States

Clinical Research Prime

🇺🇸

Idaho Falls, Idaho, United States

Deaconess Clinic, Inc.

🇺🇸

Evansville, Indiana, United States

Michael W. Simon, M.D., PSC

🇺🇸

Nicholasville, Kentucky, United States

Springs Medical Research

🇺🇸

Owensboro, Kentucky, United States

Institute of Clinical Research, LLC

🇺🇸

Mentor, Ohio, United States

Scroll for more (9 remaining)
Watching Over Mothers & Babies
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.